Literature DB >> 26995271

Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors.

Annelieke E C A B Willemsen1, Floor J E Lubberman2, Jolien Tol3, Winald R Gerritsen4, Carla M L van Herpen4, Nielka P van Erp2.   

Abstract

Oral targeted therapies represent an increasingly important group of drugs within modern oncology. With the shift from intravenously to orally administered drugs, drug absorption is a newly introduced factor in drug disposition. The process of absorption can have a large effect on inter- and intrasubject variability in drug exposure and thereby potentially treatment benefit or the severity of toxicities. The intake of oral targeted therapies with food and concomitant use of acid-reducing agents (ARAs) can significantly affect drug absorption. The size and direction of the effect of food and ARAs on drug absorption varies among drugs as a result of different chemical characteristics. Therefore, an awareness and understanding of these effects for each drug is essential to optimize patient outcomes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26995271     DOI: 10.1016/j.drudis.2016.03.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  14 in total

Review 1.  Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Authors:  Stefanie L Groenland; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2019-06-07       Impact factor: 2.953

2.  Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.

Authors:  Arzu Selen; Anette Müllertz; Filippos Kesisoglou; Rodney J Y Ho; Jack A Cook; Paul A Dickinson; Talia Flanagan
Journal:  AAPS J       Date:  2020-07-27       Impact factor: 4.009

3.  High-Tech Drugs in Creaky Formulations.

Authors:  Maikel Herbrink; Bastiaan Nuijen; Jan H M Schellens; Jos H Beijnen
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

4.  Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?

Authors:  Floor J E Lubberman; Hans Gelderblom; Carli M Wilmer; Dina M Kweekel; Ingrid M E Desar; Angela Colbers; David Burger; Winette T A van der Graaf; Nielka van Erp
Journal:  Br J Clin Pharmacol       Date:  2017-07-04       Impact factor: 4.335

5.  Development of a Novel MR Colonography via Iron-Based Solid Lipid Nanoparticles.

Authors:  Huiyang Wang; Siqi Wang; Xisong Zhu; Wenxiu Ding; Tianlun Shen; Hongjie Fan; Yanhua Zhang; Lijun Peng; Hong Yuan; Xiangrui Liu; Jun Ling; Jihong Sun
Journal:  Int J Nanomedicine       Date:  2022-02-22

Review 6.  Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Authors:  Eric D Eisenmann; Zahra Talebi; Alex Sparreboom; Sharyn D Baker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-28       Impact factor: 4.080

7.  Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.

Authors:  Kadir Eser; Arif Hakan Önder; Emel Sezer; Timuçin Çil; Ali İnal; Banu Öztürk; Vehbi Erçolak; Berna Bozkurt Duman; Halil Çelik; Tolga Köşeci; Oğuzhan Kesen
Journal:  BMC Cancer       Date:  2022-05-07       Impact factor: 4.638

8.  Soybean Milk Inhibits Absorption and Intestinal Transmembrane Transport of Gegen in Rats.

Authors:  Xiao Ling; Yuqiang Xiang; Qingfa Tang; Zhen Jin; Feilong Chen; Xiaomei Tan
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-30       Impact factor: 2.629

9.  Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.

Authors:  Roelof W F van Leeuwen; Frank G A Jansman; Nicole G Hunfeld; Robert Peric; Anna K L Reyners; Alex L T Imholz; Jacobus R B J Brouwers; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

10.  The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.

Authors:  Lotte M Knapen; Rutger H T Koornstra; Johanna H M Driessen; Bas van Vlijmen; Sander Croes; Stein Schalkwijk; Angela Colbers; Winald R Gerritsen; David M Burger; Frank de Vries; Nielka P van Erp
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.